Skip to main content

Table 1 Decreased dosage level

From: Protocol of OGSG 1901: a phase II trial of ramucirumab plus irinotecan for patients with early relapsed gastric cancer during or after adjuvant docetaxel plus S − 1 therapy

Decreased dosage level

Irinotecan

Ramucirumab

-1

120 mg/ m2

6 mg/kg

-2

100 mg/m2

5 mg/kg

-3

80 mg/m2

0 mg/m2

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us